Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 122, Issue 2, Pages 553-557Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI59309
Keywords
-
Categories
Funding
- NHMRC [628620, 566876]
- Association of International Cancer Research [10-0052]
- Pfizer
- Cancer Council Victoria
- Victorian Cancer Agency
- Victorian Breast Cancer Research Consortium, Australia
- Cure Cancer Australia Foundation and Cancer Australia
- Egyptian government
- Australian Postgraduate Research Awards
- Swiss National Science Foundation
Ask authors/readers for more resources
Mutations in the gene encoding the p110 alpha subunit of PI3K (PIK3CA) that result in enhanced PI3K activity are frequently observed in human cancers. To better understand the role of mutant PIK3CA in the initiation or progression of tumorigenesis, we generated mice in which a PIK3CA mutation commonly detected in human cancers (the H1047R mutation) could be conditionally knocked into the endogenous Pik3ca locus. Activation of this mutation in the mouse ovary revealed that alone, Pik3ca(H1047R) induced premalignant hyperplasia of the ovarian surface epithelium but no tumors. Concomitantly, we analyzed several human ovarian cancers and found PIK3CA mutations coexistent with KRAS and/or PTEN mutations, raising the possibility that a secondary defect in a co-regulator of PI3K activity may be required for mutant PIK3CA to promote transformation. Consistent with this notion, we found that Pik3ca(H1047R) mutation plus Pten deletion in the mouse ovary led to the development of ovarian serous adenocarcinomas and granulosa cell tumors. Both mutational events were required for early, robust Akt activation. Pharmacological inhibition of PI3K/mTOR in these mice delayed tumor growth and prolonged survival. These results demonstrate that the Pik3ca(H1047R) mutation with loss of Pten is enough to promote ovarian cell transformation and that we have developed a model system for studying possible therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available